Carisma Therapeutics, Inc.CARMNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P8
Near historical low
vs 5Y Ago
-2.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -63.06% |
| Q2 2025 | -14.15% |
| Q1 2025 | -50.41% |
| Q4 2024 | 51.41% |
| Q3 2024 | -6.42% |
| Q2 2024 | 2.11% |
| Q1 2024 | 3.91% |
| Q4 2023 | -20.85% |
| Q3 2023 | 10.20% |
| Q2 2023 | -32.27% |
| Q1 2023 | 813.39% |
| Q4 2022 | -74.26% |
| Q3 2022 | 55.61% |
| Q2 2022 | 21.63% |
| Q1 2022 | -76.82% |
| Q4 2021 | 412.95% |
| Q3 2021 | 54.04% |
| Q2 2021 | -79.44% |
| Q1 2021 | 54.77% |
| Q4 2020 | -16.89% |
| Q3 2020 | 24.02% |
| Q2 2020 | -3.77% |
| Q1 2020 | 4.55% |
| Q4 2019 | 1.85% |
| Q3 2019 | 23.73% |
| Q2 2019 | -14.34% |
| Q1 2019 | -12.59% |
| Q4 2018 | -8.63% |
| Q3 2018 | 62.70% |
| Q2 2018 | 20.44% |
| Q1 2018 | -1.66% |
| Q4 2017 | 21.70% |
| Q3 2017 | -27.22% |
| Q2 2017 | 1.27% |
| Q1 2017 | -19.59% |
| Q4 2016 | 7.25% |
| Q3 2016 | -26.07% |
| Q2 2016 | 61.67% |
| Q1 2016 | -7.42% |
| Q4 2015 | -13.50% |